Clinical trials: Obesity Overweight
Obesity, Overweight
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
- Trial name
- SURMOUNT-MMO (NCT05556512)
- Testing
- Tirzepatide
- Where
- 671 sites in United States, Argentina and 26 more
- Volunteers
- 15,374 people
- Sponsor
- Eli Lilly and Company
Obesity, Knee Osteoarthritis (OA)
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis.
- Trial name
- AMAZE 5 (NCT07481630)
- Testing
- NNC0487-0111
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Urinary Incontinence,Stress
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have…
- Trial name
- RESTRAIN-SUI (NCT07202884)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Canada and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Obesity, Weight Loss
ReShape Vest™ for the Treatment of Obesity (Europe)
To assess the safety and effectiveness of the LGV in treating obese subjects with a BMI of 35 kg/m2 to 55 kg/m2 who have failed one or more conservative weight-reduction alternative(s), such as supervised diet, exercise, and…
- Trial name
- NCT03918564
- Testing
- Laparoscopic Gastric Vest (LGV)
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- ReShape Lifesciences
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with…
- Trial name
- NCT01272232
- Testing
- liraglutide
- Where
- 161 sites in United States, France and 11 more
- Volunteers
- 846 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determined.
- Trial name
- NCT00404963
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nicotine Dependence, Overweight
A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects.
- Conditions
- Nicotine Dependence, Overweight, Obesity
- Trial name
- NCT00563563
- Testing
- NB32, Ancillary therapy
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Orexigen Therapeutics, Inc
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypothalamic Obesity, Prader-Willi Syndrome
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment
- Conditions
- Hypothalamic Obesity, Prader-Willi Syndrome, PWS
- Trial name
- NCT06239116
- Testing
- Part C: RM-718, Part D: RM-718
- Where
- 7 sites in United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
Prospective Multicenter Study With the Endomina® Triangulation Platform
This registry is designed to further assess on a larger scale safety and efficacy of the endomina® device and tissue apposition accessories (TAPES) when used in the frame of "real life" routine clinical practice
- Trial name
- PRETTi (NCT05677464)
- Where
- Belgium
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Endo Tools Therapeutics S.A.
Obesity, Mild
Safety & Effectiveness of TENS Weight Management Compared to a Sham
This is a multicenter, randomized, blinded, parallel group, controlled study intended to evaluate the safety and effectiveness of treating overweight and Class 1 obese patients with the Elira System (TENS active treatment)…
- Trial name
- NCT05675384
- Testing
- TENS Active Treatment
- Where
- 6 sites in United States
- Volunteers
- 395 people
- Sponsor
- Elira, Inc.
Obesity
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
- Trial name
- NCT00189514
- Testing
- pramlintide acetate
- Where
- 21 sites in United States
- Volunteers
- 210 people
- Sponsor
- AstraZeneca
Text Messaging (Intervention), Control
Text4Diet: A Text Messaging Program for Weight Loss
The purpose of the present RCT is to evaluate a 12-month SMS intervention with expanded content, intervention strategies and interactive database logic, novel online enrollment, and automatic baseline scoring of measures to…
- Trial name
- Text4Diet (NCT01571258)
- Testing
- Text Messaging
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Santech, Inc
Obesity
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part…
- Trial name
- NCT06700538
- Testing
- ARO-INHBE, Tirzepatide
- Where
- 15 sites in Australia, Canada and 2 more
- Volunteers
- 190 people
- Sponsor
- Arrowhead Pharmaceuticals
Hypertension
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure…
- Trial name
- NCT00439738
- Testing
- HCTZ + Amlodipine, Valsartan/HCTZ
- Where
- 5 sites in United States
- Volunteers
- 412 people
- Sponsor
- Novartis Pharmaceuticals
Diabete Type 2, Obesity
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D. The study will be conducted in 4 stages.
- Trial name
- NCT06104358
- Testing
- HU6
- Where
- United States
- Sponsor
- Rivus Pharmaceuticals, Inc.
Obesity and Overweight
A Study of MET233 in Individuals With Obesity or Overweight
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity.
- Trial name
- NCT07022977
- Testing
- MET233
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy.
- Trial name
- NCT07654972
- Testing
- LY4174794
- Where
- 3 sites in United States, Singapore
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Efficacy of Polyglucosamine Long Term Treatment
The polyglucosamine, specification L112, is a medical device and in this clinical trial used for weight reduction in moderately obese participants following a long term treatment lasting 12 months.
- Trial name
- NCT02682277
- Testing
- polygucosamine
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.